Open Access

Erratum to: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study

  • Maria Geitona1,
  • Hara Kousoulakou2,
  • Markos Ollandezos3,
  • Kostas Athanasakis3,
  • Sotiria Papanicolaou4Email author and
  • Ioannis Kyriopoulos3
Annals of General Psychiatry20098:15

https://doi.org/10.1186/1744-859X-8-15

Received: 17 June 2009

Accepted: 18 June 2009

Published: 18 June 2009

The original article was published in Annals of General Psychiatry 2008 7:16

Abstract

Correction to Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S and Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008, 7:16. This correction reports changes in the values listed for Ziprasidone and Aripiprazole in Table Ten.

Correction

Following the publication of our article [1], it has come to our attention that there was an error with the values listed for Ziprasidone and Aripiprazole in Table Ten. Table Ten should therefore appear as shown in this correction (Table 1).
Table 1

Mean annual number of stable days and cost per patient by pharmaceutical treatment.

 

Paliperidone ER

Olanzapine

Risperidone

Quetiapine

Ziprasidone

Aripiprazole

Base case:

Cost (€)

7.030

7.034

7.082

8.321

7.807

7.713

Effectiveness

272.5

272.2

265.5

260.7

258.6

260.5

Incremental cost and effectiveness compared with paliperidone ER:

Cost (€)

-

4

52

1.291

777

683

Effectiveness

-

-0.3

-7.0

-11.8

-13.9

-12.0

Notes

Authors’ Affiliations

(1)
Department of Economics, University of Thessaly
(2)
Institute for Economic and Industrial Research
(3)
Department of Health Economics, National School of Public Health
(4)
Janssen-Cilag Pharmaceutical SACI

References

  1. Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I: Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry. 2008, 7: 16-10.1186/1744-859X-7-16.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Geitona et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement